China–India pharmaceutical industry cooperation in the context of “One Belt, One Road”: Opportunities, challenges, and the way forward

IF 1 Q3 POLITICAL SCIENCE
M. Farooq, Feroze Nazia, Adeel Iftikhar, Cheng Tong Chun
{"title":"China–India pharmaceutical industry cooperation in the context of “One Belt, One Road”: Opportunities, challenges, and the way forward","authors":"M. Farooq, Feroze Nazia, Adeel Iftikhar, Cheng Tong Chun","doi":"10.1177/20578911221130947","DOIUrl":null,"url":null,"abstract":"To promote the “Belt and Road Initiative” (BRI) in India, it is necessary to highlight the economic attributes, highlight the role of the market, cultivate new growth points of cooperation, and consolidate the foundation of common interests. Industrial cooperation is an important part not only of the “Belt and Road” construction, but also of economic cooperation between the countries. The pharmaceutical product industry is India's most advantageous industry, and it is also an industry with which India hopes to strengthen cooperation with China. In the context of “One Belt, One Road,” China–India pharmaceutical industry cooperation faces both rare opportunities and some challenges, but from the perspective of development trends, obstacles are gradually reducing. Promoting Sino–Indian pharmaceutical industry cooperation requires the joint efforts of government departments, industry chambers of commerce, and pharmaceutical companies. The key is to choose the right cooperation field and path. Strengthening China–India pharmaceutical industry cooperation is conducive to fostering new growth points for China–India economic cooperation, reducing India's concerns about the BRI, and promoting the BRI in India and the entire South Asian region.","PeriodicalId":43694,"journal":{"name":"Asian Journal of Comparative Politics","volume":"8 1","pages":"331 - 347"},"PeriodicalIF":1.0000,"publicationDate":"2022-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Journal of Comparative Politics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/20578911221130947","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"POLITICAL SCIENCE","Score":null,"Total":0}
引用次数: 0

Abstract

To promote the “Belt and Road Initiative” (BRI) in India, it is necessary to highlight the economic attributes, highlight the role of the market, cultivate new growth points of cooperation, and consolidate the foundation of common interests. Industrial cooperation is an important part not only of the “Belt and Road” construction, but also of economic cooperation between the countries. The pharmaceutical product industry is India's most advantageous industry, and it is also an industry with which India hopes to strengthen cooperation with China. In the context of “One Belt, One Road,” China–India pharmaceutical industry cooperation faces both rare opportunities and some challenges, but from the perspective of development trends, obstacles are gradually reducing. Promoting Sino–Indian pharmaceutical industry cooperation requires the joint efforts of government departments, industry chambers of commerce, and pharmaceutical companies. The key is to choose the right cooperation field and path. Strengthening China–India pharmaceutical industry cooperation is conducive to fostering new growth points for China–India economic cooperation, reducing India's concerns about the BRI, and promoting the BRI in India and the entire South Asian region.
“一带一路”背景下的中印医药产业合作:机遇、挑战与出路
在印度推进“一带一路”倡议,要突出经济属性,突出市场作用,培育新的合作增长点,夯实共同利益基础。产业合作不仅是“一带一路”建设的重要组成部分,也是各国经济合作的重要内容。医药产品产业是印度最具优势的产业,也是印度希望与中国加强合作的产业。在“一带一路”背景下,中印医药产业合作既面临难得机遇,也面临一定挑战,但从发展趋势看,障碍正在逐步减少。推动中印医药产业合作需要政府部门、行业商会和制药公司的共同努力。关键是选择正确的合作领域和合作路径。加强中印医药产业合作,有利于培育中印经济合作新的增长点,有利于减少印度对“一带一路”倡议的担忧,有利于在印度乃至整个南亚地区推进“一带一步”倡议。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.60
自引率
0.00%
发文量
40
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信